Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;42(3):263-267.
doi: 10.1002/phar.2661. Epub 2022 Feb 3.

Perioperative cangrelor in patients with recent percutaneous coronary intervention undergoing liver transplantation: A case series

Luma Succar  1 , Chelsea N Lopez  1 , David W Victor 3rd  2   3 , Scott A Lindberg  4 , Ashish Saharia  2   5   6   7 , Samar Sheth  8 , Constance M Mobley  2   5   6   7
Affiliations

Perioperative cangrelor in patients with recent percutaneous coronary intervention undergoing liver transplantation: A case series

Luma Succar et al. Pharmacotherapy. 2022 Mar.

Abstract

Background: Management of dual antiplatelet therapy (DAPT) in the perioperative setting is challenging, particularly in complex patient populations, such as those with underlying coagulopathy and/or recent percutaneous coronary interventions.

Methods: In this case series, we describe the perioperative use of cangrelor bridge therapy in two patients undergoing liver transplantation after recent coronary drug-eluting stent placement.

Outcomes: In both patient cases, cangrelor use as a P2Y12 bridge at a dose of 0.75 μg/kg/min was safe and effective. Both patients were successfully switched back to their oral DAPT regimen post-operatively without additive bleeding or thrombotic complications.

Conclusion: The use of cangrelor as bridge therapy in high-risk perioperative liver transplant patients appears to be a viable option when DAPT is warranted.

Keywords: cangrelor; dual antiplatelet therapy (DAPT); liver transplant; perioperative.

PubMed Disclaimer

References

REFERENCES

    1. Kutkut I, Rachwan RJ, Timsina LR, et al. Pre-liver transplant cardiac catheterization is associated with low rate of myocardial infarction and cardiac mortality. Hepatology. 2020;72(1):240-256.
    1. Levine GN, Bates ER, Bittle JA, et al. 2016 Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082-1115.
    1. Valgimigli M, Bueno H, Byrne R, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260.
    1. Summary of Safety and Effectiveness Data for Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System - PMA P160043/S034: U.S. Food and Drug Administration. September 2020. SSED Template (fda.gov) Accessed September 2021.
    1. Massicotte L, Denault AY, Beaulieu D, et al. Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. Transplantation. 2012;93:1276-1281.

MeSH terms

LinkOut - more resources